Lead Product(s): DSP-0038
Therapeutic Area: Neurology Product Name: DSP-0038
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Sumitomo Dainippon Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A antagonist to be assessed for treatment of Alzheimer’s disease psychosis.